Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03909282
Other study ID # IRB-46373
Secondary ID BRS0096NCI-2019-
Status Recruiting
Phase N/A
First received
Last updated
Start date March 22, 2019
Est. completion date July 2025

Study information

Verified date March 2024
Source Stanford University
Contact Sinyoung Park
Phone 650-721-4485
Email sinyoung@stanford.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this pilot study is to compare by pathological findings surgical excision versus neoadjuvant radiotherapy followed by delayed surgical excision of ductal carcinoma in situ (DCIS)


Description:

There will be measurable histopathological treatment effects identified in Arm 2 cases receiving pre-operative radiation. Results found are expected to assist in designing a more definitive study. Compare pathological findings in individuals with ductal carcinoma in situ (DCIS) who have surgical excision versus neoadjuvant radiotherapy followed by delayed surgical excision. It is noted that "phase 2" is formally associated with drug studies. Nonetheless, it is however part of the time of this study.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date July 2025
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria - Core needle biopsy demonstrating DCIS (ductal carcinoma in situ) of non-palpable, image-detected breast abnormality - Signed and dated IRB-approved written informed consent - Women 18 years of age or older - Mammographic calcifications or MRI non-mass enhancement measuring 4 cm or less in greatest dimension, including multifocal disease - Estrogen receptor positive or negative, progesterone receptor positive or negative DCIS; HER2 positive, negative or unknown DCIS is allowed. - Diagnostic needle biopsy within 16 weeks of randomization - Patients must have a biopsy marker placed within the tumor bed confirmed on post biopsy imaging and evidence of residual radiographic abnormality. Confirmation of residual imaging abnormality is required within 6 weeks of randomization. - Placement of Savi scout optical reflectance marker in tumor bed area as a wireless guide for surgery and for neoRT treatment planning is preferred but not required if anatomic metallic markers are sufficient for radiation planning. Placement does not have to occur before randomization. Additionally, wire localization before surgery is permissible. - Planned lumpectomy. Mastectomy will be acceptable if lumpectomy fails by virtue of involved margins or size of lesion, or patient chooses this approach after randomization - Radiation Oncologist to ascertain feasibility of PBI prior to randomization - based on their estimation that 30% or less of the breast volume will be encompassed in the radiation fields - Patients who had a prior contralateral invasive or non-invasive (DCIS) cancer are eligible - ECOG performance status 0, 1, or 2 - Concurrent foci of atypia or lobular carcinoma in situ in the ipsilateral or contralateral breast are allowed Exclusion Criteria - Invasive carcinoma on core needle biopsy, including microinvasive carcinoma - Radiographic extent of DCIS >4.0 cm - Mass lesion on breast imaging or palpable tumor - No residual radiographic lesion after diagnostic percutaneous core needle biopsy - Prior history of ipsilateral invasive or noninvasive breast cancer - Pregnant or breastfeeding - Prior ipsilateral breast or chest irradiation - Multicentric or multifocal DCIS, if extent is > 4cm - Synchronous contralateral invasive or noninvasive breast cancer - Pagets' disease of the breast - Active collagen vascular disease - Positive axillary lymph nodes - Not meeting the described criteria for partial breast irradiation during initial clinical evaluation. - Psychiatric or addictive disorders or other condition, that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with the interpretation of study results - Endocrine therapy is not allowed from the time of study randomization to the completion of surgery unless the endocrine therapy is being continued for a contralateral cancer

Study Design


Intervention

Procedure:
Lumpectomy
Standard of Care surgery for DCIS (either lumpectomy or mastectomy)
Radiation:
Partial breast irradiation prior to surgery
Partial breast irradiation (PBI) will be delivered once aday for 5 days. The planned daily dose is 6 Gy prior to surgery (neo adjuvant)

Locations

Country Name City State
United States Stanford University Stanford California

Sponsors (1)

Lead Sponsor Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of ductal carcinoma in situ (DCIS) pathologic complete response A DCIS pathologic complete response will be defined as the absence of in situ carcinoma in the surgical resection specimen. The rate of DCIS pathologic complete response (pCR) will be calculated for Arm 1 and Arm 2. 12 weeks
Secondary Correlation of ductal carcinoma in situ (DCIS) subtypes with rate of DCIS pathologic complete response to neoadjuvant partial breast irradiation (PBI) Molecular subtypes based on gene expression profiling with therapy response will be corelated.
• DCIS subtypes will be defined based on grade, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status as follows:
Low/intermediate grade versus high grade
ER/PR-negative versus ER/PR-positive
HER2-positive versus HER2-negative
12 weeks
Secondary Tumor grade comparison of radiation-induced treatment effect pathologically pre- versus post-therapy Tumor grade (grade 1, 2, 3) will be compared pre- and post-therapy. 12 weeks
Secondary Nuclear atypia comparison of radiation-induced treatment effect pathologically pre- versus post-therapy Degree of nuclear atypia (low, intermediate, high) will be compared pre- and post-therapy. 12 weeks
Secondary Percent tumor necrosis comparison of radiation-induced treatment effect pathologically pre- versus post-therapy Percent tumor necrosis (0-100%) will be quantified on the basis of percentage of overall residual tumor area and compared pre- and post-treatment. 12 weeks
Secondary Tumor cellularity comparison of radiation-induced treatment effect pathologically pre- versus post-therapy Tumor cellularity (0-100%) will be quantified on the basis of percentage of overall residual tumor area and compared pre- and post-treatment. 12 weeks
Secondary Proportion of subjects experiencing a wound complication on Arm 1 compared to Arm 2 Wound complications and healing will be monitored in both arms.The following events will be considered wound complications: wound dehiscence, hematoma requiring intervention, seroma requiring drainage, skin necrosis requiring resection, cellulitis requiring antibiotic therapy. 12 weeks
Secondary Correlation of post-radiation imaging characteristics with pathologic findings Mammography obtained prior to surgical resection in Arm 2 patients will be assessed for the presence or absence of a residual mammographic abnormality, the size in mm of the residual mammographic abnormality and the longest span in mm of residual calcification and will be compared to the pathologic presence or absence of residual tumor, size in mm of the pathologic residual DCIS and whether the residual calcification is associated with pathologic residual DCIS. 12 weeks
Secondary Rate of invasive carcinoma comparison in Arm 1 to Arm 2 Rate of pathologic residual invasive carcinoma will be assessed in Arm 1 and Arm 2. 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT02314156 - Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy Phase 2
Completed NCT01874184 - Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer N/A
Active, not recruiting NCT01905046 - Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer Phase 3
Completed NCT01869764 - Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer Phase 2
Completed NCT02587663 - Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI N/A
Active, not recruiting NCT04537312 - Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM) N/A
Active, not recruiting NCT01245712 - Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer Phase 2
Recruiting NCT02993159 - Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast Phase 2
Completed NCT01753908 - Broccoli Sprout Extract in Treating Patients With Breast Cancer Early Phase 1
Terminated NCT02023008 - Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy N/A
Terminated NCT01754519 - Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery Phase 2
Completed NCT01849250 - Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors Phase 2
Completed NCT01819233 - Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy N/A
Active, not recruiting NCT03077841 - Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer Phase 2/Phase 3
Active, not recruiting NCT02352883 - MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ N/A
Completed NCT01723943 - Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients N/A
Completed NCT00637481 - A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer Phase 1
Completed NCT01975363 - Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer N/A
Active, not recruiting NCT03391388 - 3D-CRT, Proton, or Brachytherapy APBI in Treating Patients With Invasive and Non-invasive Breast Cancer Phase 2
Completed NCT02526498 - Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery Phase 2